Abstract

The Endoscopic Injection Sclerotherapy(EIS) has been widely adopted as a primary treatment for acute hemorrhage from esophageal varices. The long term repeated EIS could achieve esophageal variceal obliteration which has been regarded as the endpoint of sclerotherapy by many authors. Several studies showed that repeated EIS improved the long-term survival, and reduced the bleeding episodes. However, in recent prospective randomized trials, the frequency of bleeding was not reduced and even increasd without improvement of survival in patients undergoing prophylactic sclerotherapy.